CoChat

Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Open access
Chari, Ajai, Martinez-Lopez, Joaquín, Mateos, María-Victoria, Bladé, Joan, Benboubker, Lotfi, Oriol, Albert, Arnulf, Bertrand, Rodriguez-Otero, Paula, Pineiro, Luis, Jakubowiak, Andrzej, de Boer, Carla, Wang, Jianping, Clemens, Pamela L., Ukropec, Jon, Schecter, Jordan, Lonial, Sagar, Moreau, Philippe · 2019 · Blood
Cited by 136

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy for frontline treatment of multiple myeloma has resulted in a need for effective regimens for lenalidomide-refractory patients. This phase 1b study evaluated daratumumab plus carfilzomib and dexamethasone (D-Kd) in patients with RRMM after 1 to 3 prior lines of therapy, including bortezomib and an immunomodulatory drug; lenalidomide-refractory patients were eligible. Carfilzomib- and daratumumab-naïve patients (n = 85) received carfilzomib weekly on days 1, 8, and 15 of each 28-day cycle (20 mg/m2 initial dose, escalated to 70 mg/m2 thereafter) and dexamethasone (40 mg/wk). Of these, 10 patients received the first daratumumab dose as a single infusion (16 mg/kg, day 1 cycle 1), and 75 patients received a split first dose (8 mg/kg, days 1-2 cycle 1). Subsequent dosing was per the approved schedule for daratumumab. Patients received a median of 2 (range, 1-4) prior lines of therapy; 60% were lenalidomide refractory. The most common grade 3/4 treatment-emergent adverse events were thrombocytopenia (31%), lymphopenia (24%), anemia (21%), and neutropenia (21%). Infusion-related reactions were observed in 60% and 43% of single and split first-dose patients, respectively. Overall response rate was 84% (79% in lenalidomide-refractory patients). Median progression-free survival (PFS) was not reached; 12-month PFS rates were 74% for all treated patients and 65% for lenalidomide-refractory patients. D-Kd was well tolerated with low neutropenia rates, and it demonstrated deep responses and encouraging PFS, including in patients refractory to lenalidomide. The trial was registered at www.clinicaltrials.gov as #NCT01998971.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019000722

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 136

Metadata

Authors
Chari, A., Martinez-Lopez, J., Mateos, M.-V., Bladé, J., Benboubker, L., Oriol, A., Arnulf, B., Rodriguez-Otero, P., Pineiro, L., Jakubowiak, A., de Boer, C., Wang, J., Clemens, P. L., Ukropec, J., Schecter, J., Lonial, S., & Moreau, P.
Venue
Blood
Published
2019-08-01
Volume
134
Issue
5
Pages
421-431
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2945434115
Cited by
136
References
10
FWCI
15.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. https://app.cochat.ai/papers/10.1182/blood.2019000722
The paper
Chari, A., Martinez-Lopez, J., Mateos, M.-V., Bladé, J., Benboubker, L., Oriol, A., Arnulf, B., Rodriguez-Otero, P., Pineiro, L., Jakubowiak, A., de Boer, C., Wang, J., Clemens, P. L., Ukropec, J., Schecter, J., Lonial, S., & Moreau, P. (2019). Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. https://doi.org/10.1182/blood.2019000722

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.